Menstrual and Uterine Disorders
endometriosis, chronic pelvic pain and dysmenorrheal, Contraception, 2007;75:134–9.
14. Fedele L, Bianchi S, Zanconato G, et al., Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis, Fertil Steril, 2001;75:485–8.
15. Petraglia F, Lazzeri L, De Bonis M, Luisi S. The role of progestogens in endometriosis therapy. Gynaecology Forum, 2010;11.
16. Vercellini P, De Giorgi O, Oldani S, et al., Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis, Am J Obstet Gynecol, 1996;175:396–401.
17. Razzi S, Luisi S, Ferretti C, et al., Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis, Eur J Obstet Gynecol Reprod Biol, 2007;135:188–90.
18. Sasagawa S, Shimizu Y, Kami H, et al., Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile, Steroids, 2008;73:222–31.
19. Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study, Eur J Obstet Gynecol Reprod Biol, 2010;151:193–8.
20. Harada T, Momoeda M, Taketani Y, et al., Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis, a randomized, double-blind, multicenter, controlled trial, Fertil Steril, 2009;91:675–81.
21. Strowitzki T, Marr J, Gerlinger C, et al., Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial, Hum Reprod, 2010;25:633–41.
22. Petraglia F, Hornung D, Seitz C, et al., Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment, Arch Gynecol Obstet, 2011;[in press].
23. Practice Commitee of the American Society for Reproductive Medicine, Treatment of pelvic pain associated with endometriosis, Fertil Steril, 2008;3:260–9.
24. Vercellini P, Eskenazi B, Consonni D, et al., Oral contraceptives and endometriosis: dangerous liason or protective measure? A systematic review and meta analysis, Hum Reprod Update, 2011;17:159–70.
25. Kennedy S, Bergqvist A, Chapron C, et al., ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and
treatment of endometriosis, Hum Reprod, 2005;20:2698–704.
26. Somigliana E, Vercellini P, Vigano P, et al., Endometriosis and estroprogestins: the chicken or the egg causality dilemma, Fertil Steril, 2011;95:431–3.
27. Chapron C, Souza C, Borghese B, et al., Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis, Hum Reprod, 2011;26:2028–35.
28. Seracchioli R, Mabrouk M, Manuzzi L, et al., Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis, Hum Reprod, 2009;24:2729–35.
29. Takamura M, Koga K, Osuga Y, et al., Post-operative oral contraceptive use reduces the risk of ovarian endometrioma recurrence after laparoscopic excision, Hum Reprod, 2009;24:3042–8.
30. Vercellini P, Frontino G, De Giorgi O, et al., Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen, Fertil Steril, 2003;80:560–3.
31. Nelson LR, Bulun SE, Estrogen production and action, J Am Acad Dermatol, 2001;45:116–24.
32. Buzdar A, Howell A, Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer, Clin Cancer Res, 2001;7:2620–35.
33. Amsterdam LL, Gentry W, Jobanputra S, et al., Anastrazole and oral contraceptives: a novel treatment for endometriosis, Fertil Steril, 2005;84:300–4.
34. Razzi S, Fava A, Sartini A, et al., Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman, BJOG, 2004;111:182–4.
35. Lossl K, Loft A, Freiesleben NL, et al., Combined down- regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas – A pilot study, Eur J Obstet Gynecol Reprod Biol, 2009;144:48–53.
36. Healey S, Tan SL, Tulandi T, Biljan MM. Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine insemination, Fertil Steril, 2003;80:1325–9.
37. Folkman J, Shing Y, Angiogenesis, J Biol Chem, 1992;267:10931–4.
38. Donnez J, Smoes P, Gillerot S, et al., Vascular endothelial growth factor (VEGF) in endometriosis, Hum Reprod, 1998;13:1686–90.
39. Ferrara N, Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications, Semin Oncol, 2002;29:10–4.
40 McCarty MF, Liu W, Fan F, et al., Promises and pitfalls of anti-angiogenic therapy in clinical trials, Trends Mol Med, 2003;9:53–8.
41. Kressin P, Wolber EM, Wodrich H, et al., Vascular endothelial growth factor mRNA in eutopic and ectopic endometrium, Fertil Steril, 2001;76:1220–4.
42. Van Langendonckt A, Donnez J, Defrère S, et al., Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises, Mol Hum Reprod, 2008;14:259–68.
43. Nap AW, Griffioen AW, Dunselman GA, et al., Antiangiogenesis therapy for endometriosis, J Clin Endocrinol Metab, 2004;89:1089–95.
44. Novella-Maestre E, Carda C, Noguera I, et al., Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis, Hum Reprod, 2009;24:1025–35.
45. Pauli SA, Tang H, Wang J, et al., The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the roden, Endocrinology, 2005;146:1301–11.
46. Moravek MB, Ward EA, Lebovic DI. Thiazolidinediones as therapy for endometriosis: a case series, Gynecol Obstet Invest, 2009;68:167–70.
47. Kalyoncu NI, Yaris F, Ulku C, et al., A case of rosiglitazoneexposure in the second trimester of pregnancy, Reprod Toxicol, 2005;19:563–4.
48. Novembri R, Luisi S, Carrarelli P, et al., Omega 3 fatty acids counteract IL-8 and prostaglandin E2 secretion induced by
TNF-α in cultured endometrial stromal cells, Journal of Endometriosis, 2011;3:34–9.
49. Wieser F, Cohen M, Gaeddert A, et al., Evolution of medical treatment for endometriosis: back to the roots?, Hum Reprod Update, 2007;13:487–99.
50. Danesh FR, Sadeghi MM, Amro N, et al., 3-Hydroxy-3- methylglutaryl CoA reductase inhibitors prevent high glucose- induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy, Proc Natl Acad Sci USA, 2002;99:8301–5.
51. Mattingly RR, Gibbs RA, Menard RE, Reiners JJ Jr., Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3- allylfarnesol, an inhibitor of protein farnesyltransferase, J Pharmacol Exp Ther, 2002;303:74–81.
52. Foyouzi N, Berkkanoglu M, Arici A, et al., Effects of oxidants and antioxidants on proliferation of endometrial stromal cells, Fertil Steril, 2004;82:1019–22.
US OBSTETRICS & GYNECOLOGY
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68